Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C.

Mult Scler. 2019 May 8:1352458519845844. doi: 10.1177/1352458519845844. [Epub ahead of print]

PMID:
31066634
2.

Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study.

Cuello JP, Martínez Ginés ML, Kuhle J, García Domínguez JM, Lozano Ros A, Romero Delgado F, Higueras Y, Meldaña Rivera A, Goicochea Briceño H, García-Tizon Larroca S, de-León Ruiz J, Michalak Z, Barro C, Álvarez Lafuente R, Medina Heras S, Fernández Velasco JI, Tejeda-Velarde A, Domínguez-Mozo MI, Muriel A, de Andrés C, Villar LM.

Eur J Neurol. 2019 Apr 12. doi: 10.1111/ene.13965. [Epub ahead of print]

PMID:
30977955
3.

Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients.

Medina S, Sainz de la Maza S, Villarrubia N, Álvarez-Lafuente R, Costa-Frossard L, Arroyo R, Monreal E, Tejeda-Velarde A, Rodríguez-Martín E, Roldán E, Álvarez-Cermeño JC, Villar LM.

Ann Clin Transl Neurol. 2019 Jan 15;6(2):355-363. doi: 10.1002/acn3.711. eCollection 2019 Feb.

4.

Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis.

Pérez-Pérez S, Domínguez-Mozo MI, García-Martínez MÁ, Aladro Y, Martínez-Ginés M, García-Domínguez JM, López de Silanes C, Casanova I, Ortega-Madueño I, López-Lozano L, Torrejón MJ, Arroyo R, Álvarez-Lafuente R.

Eur J Neurol. 2018 Dec;25(12):1446-1453. doi: 10.1111/ene.13749. Epub 2018 Aug 3.

PMID:
29996002
5.

Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the 'hygiene hypothesis'?

Alari-Pahissa E, Moreira A, Zabalza A, Alvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Alvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE.

Eur J Neurol. 2018 Jul;25(7):925-933. doi: 10.1111/ene.13622. Epub 2018 Apr 15.

PMID:
29528545
6.

New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis.

Ortiz MA, Espino-Paisan L, Nunez C, Alvarez-Lafuente R, Urcelay E.

Curr Med Chem. 2018;25(27):3272-3283. doi: 10.2174/0929867325666180226105612. Review.

PMID:
29484976
7.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
8.

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, Sainz de la Maza S, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM.

J Neurol. 2018 Jan;265(1):32. doi: 10.1007/s00415-017-8679-5.

PMID:
29177546
9.

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, de la Maza SS, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM.

J Neurol. 2018 Jan;265(1):24-31. doi: 10.1007/s00415-017-8625-6. Epub 2017 Oct 12. Erratum in: J Neurol. 2017 Nov 24;:.

PMID:
29027004
10.

Multimarker risk stratification approach at multiple sclerosis onset.

Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM, Pérez de Diego R, Alonso B, Álvarez Cermeño JC, Arroyo R, Tejera-Alhambra M, Navarro J, Oreja-Guevara C, López Trascasa M, Seyfferth A, García Martínez MA, Álvarez Lafuente R, Albert ML, Sánchez-Ramón S.

Clin Immunol. 2017 Aug;181:43-50. doi: 10.1016/j.clim.2017.05.019. Epub 2017 May 31.

PMID:
28578025
11.

Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.

Sisay S, Lopez-Lozano L, Mickunas M, Quiroga-Fernández A, Palace J, Warnes G, Alvarez-Lafuente R, Dua P, Meier UC.

J Neuroimmunol. 2017 May 15;306:40-45. doi: 10.1016/j.jneuroim.2017.02.017. Epub 2017 Mar 2.

PMID:
28385186
12.

Metabolomic signatures associated with disease severity in multiple sclerosis.

Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 27;4(2):e321. doi: 10.1212/NXI.0000000000000321. eCollection 2017 Mar.

13.

Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.

Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.

Eur J Clin Invest. 2017 Feb;47(2):158-166. doi: 10.1111/eci.12721.

PMID:
28036121
14.

Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid.

Galán Sánchez-Seco V, Casanova-Peño I, Álvarez-Lafuente R, Sánchez-Jiménez M, García-Martínez Á, Domínguez-Mozo MI, Arias-Leal AM, García-Montojo M, Arroyo-González R.

Clin Neuropharmacol. 2017 Jan/Feb;40(1):29-33. doi: 10.1097/WNF.0000000000000196.

PMID:
27879549
15.

JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab.

Domínguez-Mozo MI, Toledano-Martínez E, Rodríguez-Rodríguez L, García-Montojo M, Alvarez-Lafuente R, Fernández-Gutiérrez B.

Scand J Rheumatol. 2016 Nov;45(6):507-511. Epub 2016 Apr 11.

PMID:
27063911
16.

Multiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion.

Varadé J, García-Montojo M, de la Hera B, Camacho I, García-Martínez MÁ, Arroyo R, Álvarez-Lafuente R, Urcelay E.

BBA Clin. 2015 Feb 19;3:162-7. doi: 10.1016/j.bbacli.2015.02.002. eCollection 2015 Jun.

17.

Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.

Domínguez-Mozo MI, García-Montojo M, Arias-Leal A, García-Martínez Á, Santiago JL, Casanova I, Galán V, Arroyo R, Fernández-Arquero M, Alvarez-Lafuente R.

Eur J Neurol. 2016 Jan;23(1):182-9. doi: 10.1111/ene.12834. Epub 2015 Oct 25.

PMID:
26498276
18.

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct.

19.

Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.

Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M.

Mult Scler. 2016 May;22(6):741-52. doi: 10.1177/1352458515601215. Epub 2015 Sep 11.

PMID:
26362897
20.

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.

Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30.

PMID:
25581547
21.

Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis.

Ortega-Madueño I, Garcia-Montojo M, Dominguez-Mozo MI, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R.

PLoS One. 2014 Aug 11;9(8):e104836. doi: 10.1371/journal.pone.0104836. eCollection 2014.

22.

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

Villar LM, Casanova B, Ouamara N, Comabella M, Jalili F, Leppert D, de Andrés C, Izquierdo G, Arroyo R, Avşar T, Lapin SV, Johnson T, Montalbán X, Fernández O, Álvarez-Lafuente R, Masterman D, García-Sánchez MI, Coret F, Siva A, Evdoshenko E, Álvarez-Cermeño JC, Bar-Or A.

Ann Neurol. 2014 Aug;76(2):231-40. doi: 10.1002/ana.24190. Epub 2014 Jul 2.

PMID:
24909126
23.

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.

Núñez C, Cénit MC, Alvarez-Lafuente R, Río J, Fernández-Arquero M, Arroyo R, Montalbán X, Fernández O, Oliver-Martos B, Leyva L, Comabella M, Urcelay E.

J Med Genet. 2014 Jun;51(6):395-400. doi: 10.1136/jmedgenet-2014-102348. Epub 2014 Apr 19.

PMID:
24748646
24.

Identification of the major HHV-6 antigen recognized by cerebrospinal fluid IgG in multiple sclerosis.

Alenda R, Álvarez-Lafuente R, Costa-Frossard L, Arroyo R, Mirete S, Álvarez-Cermeño JC, Villar LM.

Eur J Neurol. 2014 Aug;21(8):1096-1101. doi: 10.1111/ene.12435. Epub 2014 Apr 12.

PMID:
24724742
25.

Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysis.

de la Hera B, Varadé J, García-Montojo M, Alcina A, Fedetz M, Alloza I, Astobiza I, Leyva L, Fernández O, Izquierdo G, Antigüedad A, Arroyo R, Álvarez-Lafuente R, Vandenbroeck K, Matesanz F, Urcelay E.

PLoS One. 2014 Mar 3;9(3):e90182. doi: 10.1371/journal.pone.0090182. eCollection 2014.

26.

HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.

García-Montojo M, de la Hera B, Varadé J, de la Encarnación A, Camacho I, Domínguez-Mozo M, Árias-Leal A, García-Martínez A, Casanova I, Izquierdo G, Lucas M, Fedetz M, Alcina A, Arroyo R, Matesanz F, Urcelay E, Alvarez-Lafuente R.

Retrovirology. 2014 Jan 9;11:2. doi: 10.1186/1742-4690-11-2.

27.

Classification of HHV-6A and HHV-6B as distinct viruses.

Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N, Gallo R, Gompels UA, Höllsberg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T.

Arch Virol. 2014 May;159(5):863-70. doi: 10.1007/s00705-013-1902-5. Epub 2013 Nov 6. Review.

28.

Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.

Dominguez-Mozo MI, Garcia-Montojo M, De Las Heras V, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1277-86. doi: 10.1007/s11481-013-9496-y. Epub 2013 Aug 25.

PMID:
23979860
29.

Toll-like receptor-9 in Spanish multiple sclerosis patients: an association with the gender.

Dominguez-Mozo MI, Garcia-Montojo M, López-Cavanillas M, De Las Heras V, Garcia-Martinez A, Arias-Leal AM, Casanova I, Urcelay E, Arroyo R, Alvarez-Lafuente R.

Eur J Neurol. 2014 Mar;21(3):537-40. doi: 10.1111/ene.12209. Epub 2013 Jun 4.

PMID:
23731219
30.

Expression of human endogenous retrovirus HERV-K18 is associated with clinical severity in osteoarthritis patients.

Garcia-Montojo M, Varade J, Villafuertes E, de La Hera B, Hoyas-Fernandez J, Domínguez-Mozo MI, Rodriguez-Rodriguez L, Tornero-Esteban P, Arias-Leal A, León L, Lamas JR, Alvarez-Lafuente R, Urcelay E, Fernandez-Gutierrez B.

Scand J Rheumatol. 2013;42(6):498-504. doi: 10.3109/03009742.2013.779021. Epub 2013 May 11.

PMID:
23662747
31.

Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.

López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, Fernández Ó, Leyva L.

PLoS One. 2013 Apr 29;8(4):e62540. doi: 10.1371/journal.pone.0062540. Print 2013.

32.

Role of the human endogenous retrovirus HERV-K18 in autoimmune disease susceptibility: study in the Spanish population and meta-analysis.

de la Hera B, Varadé J, García-Montojo M, Lamas JR, de la Encarnación A, Arroyo R, Fernández-Gutiérrez B, Alvarez-Lafuente R, Urcelay E.

PLoS One. 2013 Apr 25;8(4):e62090. doi: 10.1371/journal.pone.0062090. Print 2013.

33.

Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis.

Lamas JR, Rodríguez-Rodríguez L, Tornero-Esteban P, Villafuertes E, Hoyas J, Abasolo L, Varadé J, Alvarez-Lafuente R, Urcelay E, Fernández-Gutiérrez B.

Cytokine. 2013 Mar;61(3):720-3. doi: 10.1016/j.cyto.2012.12.025. Epub 2013 Jan 29.

PMID:
23375120
34.

The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity.

Garcia-Montojo M, Dominguez-Mozo M, Arias-Leal A, Garcia-Martinez Á, De las Heras V, Casanova I, Faucard R, Gehin N, Madeira A, Arroyo R, Curtin F, Alvarez-Lafuente R, Perron H.

PLoS One. 2013;8(1):e53623. doi: 10.1371/journal.pone.0053623. Epub 2013 Jan 7.

35.

MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up.

Dominguez-Mozo MI, Garcia-Montojo M, De Las Heras V, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R.

BMC Neurol. 2012 Sep 25;12:107. doi: 10.1186/1471-2377-12-107.

36.

Herpesvirus active replication in multiple sclerosis: a genetic control?

Garcia-Montojo M, Martinez A, De Las Heras V, Dominguez-Mozo MI, Cenit Mdel C, López-Cavanillas M, Garcia-Martinez A, Arias-Leal AM, Gomez de la Concha E, Urcelay E, Arroyo R, Alvarez-Lafuente R.

J Neurol Sci. 2011 Dec 15;311(1-2):98-102. doi: 10.1016/j.jns.2011.09.001. Epub 2011 Oct 1.

PMID:
21962857
37.

IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis.

Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, Lechner-Scott J, Urcelay E, Fernández O, Drulovic J, García-Merino A, Martinelli Boneschi F, Chan A, Vandenbroeck K, Navarro A, Bustamante MF, Río J, Akkad DA, Giacalone G, Sánchez AJ, Leyva L, Alvarez-Lafuente R, Zettl UK, Oksenberg J, Montalban X, Comabella M.

J Neuroimmunol. 2011 Oct 28;239(1-2):101-4. doi: 10.1016/j.jneuroim.2011.08.004. Epub 2011 Sep 1.

PMID:
21889215
38.

TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis.

López-Gómez C, Fernández O, García-León JA, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Suardíaz M, García-Trujillo L, Guijarro-Castro C, Benito-León J, Prat I, Varadé J, Álvarez-Lafuente R, Urcelay E, Leyva L.

PLoS One. 2011;6(7):e21766. doi: 10.1371/journal.pone.0021766. Epub 2011 Jul 21.

39.

Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.

Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, Bartolome M, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R; HHV-6 and Multiple Sclerosis Study Group.

Eur J Neurol. 2011 Aug;18(8):1027-35. doi: 10.1111/j.1468-1331.2011.03410.x. Epub 2011 Apr 25.

PMID:
21518144
40.

CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.

Alvarez-Lafuente R, Blanco-Kelly F, Garcia-Montojo M, Martínez A, De Las Heras V, Dominguez-Mozo MI, Bartolome M, Garcia-Martinez A, De la Concha EG, Urcelay E, Arroyo R.

Mult Scler. 2011 May;17(5):513-20. doi: 10.1177/1352458510393263. Epub 2010 Dec 21.

PMID:
21177319
41.

Members 6B and 14 of the TNF receptor superfamily in multiple sclerosis predisposition.

Blanco-Kelly F, Alvarez-Lafuente R, Alcina A, Abad-Grau MM, de Las Heras V, Lucas M, de la Concha EG, Fernández O, Arroyo R, Matesanz F, Urcelay E.

Genes Immun. 2011 Mar;12(2):145-8. doi: 10.1038/gene.2010.42. Epub 2010 Oct 21.

PMID:
20962851
42.

Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection.

Vandenbroeck K, Alloza I, Swaminathan B, Antigüedad A, Otaegui D, Olascoaga J, Barcina MG, de las Heras V, Bartolomé M, Fernández-Arquero M, Arroyo R, Alvarez-Lafuente R, Cénit MC, Urcelay E.

Genes Immun. 2011 Jan;12(1):40-5. doi: 10.1038/gene.2010.46. Epub 2010 Sep 23.

PMID:
20861862
43.

Large-scale gene expression in bone marrow mesenchymal stem cells: a putative role for COL10A1 in osteoarthritis.

Lamas JR, Rodríguez-Rodríguez L, Vigo AG, Alvarez-Lafuente R, López-Romero P, Marco F, Camafeita E, Dopazo A, Callejas S, Villafuertes E, Hoyas JA, Tornero-Esteban MP, Urcelay E, Fernández-Gutiérrez B.

Ann Rheum Dis. 2010 Oct;69(10):1880-5. doi: 10.1136/ard.2009.122564. Epub 2010 May 24.

PMID:
20498197
44.

Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.

Garcia-Montojo M, Dominguez-Mozo MI, de las Heras V, Bartolome M, Garcia-Martinez A, Arroyo R, Alvarez-Lafuente R.

Eur J Neurol. 2010 Mar;17(3):470-8. doi: 10.1111/j.1468-1331.2009.02890.x. Epub 2009 Dec 27.

PMID:
20050906
45.

MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients.

Alvarez-Lafuente R, Martinez A, Garcia-Montojo M, Mas A, De Las Heras V, Dominguez-Mozo MI, Maria Del Carmen C, López-Cavanillas M, Bartolome M, Gomez de la Concha E, Urcelay E, Arroyo R.

Eur J Neurol. 2010 Jan;17(1):129-35. doi: 10.1111/j.1468-1331.2009.02758.x. Epub 2009 Jul 29.

PMID:
19659749
46.

CD46 expression and HHV-6 infection in patients with multiple sclerosis.

Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Dominguez-Mozo MI, Bartolome M, Arroyo R.

Acta Neurol Scand. 2009 Oct;120(4):246-50. doi: 10.1111/j.1600-0404.2009.01163.x. Epub 2009 May 13.

PMID:
19456309
47.

The ubiquitin-proteasome pathway and viral infections in articular cartilage of patients with osteoarthritis.

Rollín R, Alvarez-Lafuente R, Marco F, López-Durán L, Hoyas JA, Jover JA, Fernández-Gutiérrez B.

Rheumatol Int. 2009 Jun;29(8):969-72. doi: 10.1007/s00296-009-0891-x. Epub 2009 Mar 22.

PMID:
19306096
48.

Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients.

Alvarez-Lafuente R, García-Montojo M, De Las Heras V, Domínguez-Mozo MI, Bartolome M, Benito-Martin MS, Arroyo R.

Mult Scler. 2008 Jun;14(5):595-601. doi: 10.1177/1352458507086425.

PMID:
18566025
49.

Multicenter comparison of PCR assays for detection of human herpesvirus 6 DNA in serum.

Flamand L, Gravel A, Boutolleau D, Alvarez-Lafuente R, Jacobson S, Malnati MS, Kohn D, Tang YW, Yoshikawa T, Ablashi D.

J Clin Microbiol. 2008 Aug;46(8):2700-6. doi: 10.1128/JCM.00370-08. Epub 2008 Jun 11. Erratum in: J Clin Microbiol. 2009 Feb;47(2):519.

50.

Detection of human herpesvirus-6, Epstein-Barr virus and cytomegalovirus in formalin-fixed tissues from sudden infant death: a study with quantitative real-time PCR.

Alvarez-Lafuente R, Aguilera B, Suárez-Mier MA, Morentin B, Vallejo G, Gómez J, Fernández-Rodríguez A.

Forensic Sci Int. 2008 Jul 4;178(2-3):106-11. doi: 10.1016/j.forsciint.2008.02.007.

PMID:
18424026

Supplemental Content

Loading ...
Support Center